We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current ARQT market cap is 1.52B. The company's latest EPS is USD -2.2397 and P/E is -5.81.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 38.11M | 13.53M | 49.57M | 30.86M | 44.76M |
| Operating Income | -36.9M | -61.17M | -31.62M | -50.08M | -39.07M |
| Net Income | -44.77M | -66.28M | -35.38M | -52.33M | -41.54M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 3.69M | 59.61M |
| Operating Income | -43.13M | -136.65M | -206.53M | -301.63M | -241.1M |
| Net Income | -42M | -135.68M | -206.36M | -311.46M | -262.14M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 292.96M | 341.37M | 478.54M | 444.76M | 437.35M |
| Total Liabilities | 246.24M | 252.7M | 253.6M | 258.33M | 280.71M |
| Total Equity | 46.72M | 88.67M | 224.94M | 186.43M | 156.64M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 107.01M | 298.27M | 408.15M | 449.27M | 341.37M |
| Total Liabilities | 5.55M | 27.65M | 110.48M | 239.69M | 252.7M |
| Total Equity | -65.03M | 270.62M | 297.68M | 209.58M | 88.67M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -190.81M | -247.06M | -31.6M | -76.72M | -111.41M |
| Investing | 242.42M | 180.23M | -28.7M | -90.83M | -6.06M |
| Financing | 2.03M | 101.32M | 161.76M | 163.22M | 163.61M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -42.84M | -113.03M | -174.63M | -257.72M | -247.06M |
| Investing | -26.33M | -181.82M | -75.95M | -87.2M | 180.23M |
| Financing | 93.1M | 298.15M | 281.95M | 301.8M | 101.32M |
| Market Cap | 1.52B |
| Price to Earnings Ratio | -5.81 |
| Price to Sales Ratio | 25.54 |
| Price to Cash Ratio | 17.22 |
| Price to Book Ratio | 17.17 |
| Dividend Yield | - |
| Shares Outstanding | 117.04M |
| Average Volume (1 week) | 1.68M |
| Average Volume (1 Month) | 2.28M |
| 52 Week Change | 38.51% |
| 52 Week High | 16.20 |
| 52 Week Low | 6.99 |
| Spread (Intraday) | 0.35 (2.63%) |
| Company Name | Arcutis Biotherapeutics Inc |
| Address |
3411 silverside road tatnall wilmington, delaware 19810 |
| Website | https://www.arcutis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
